ABSTRACT
BACKGROUND This study is focused to identify the risk factors of shunt-dependent hydrocephalus (SDHC) after aneurysmal subarachnoid hemorrhage (aSAH) and develop a model to predict its incidence.
METHODS Medical records of 118 consecutive patients with aSAH treated in our institution from January 2013 to October 2021 were reviewed retrospectively, 109 of them were enrolled in this cohort, the following data were analyzed based on presence or absence of SDHC: age, gender, body mass index, Fisher grade, Hunt and Hess scale (HHS), aneurysm location, treatment modality, new neurological deficits after aneurysm treatment, estimated glomerular filtration rate (eGFR), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and platelet-neutrophil ratio (PNR). We conducted univariate and multivariate logistic regression analyses to illustrate a nomogram for predicting SDHC risk.
RESULTS The stepwise logistic regression analysis with backward selection revealed three independent predictive factors of SDHC: age ≥65 (odds ratio, 3.94; 95% CI, 1.4–11.00; p = 0.009), treatment modality (odds ratio, 4.36; 95% CI, 1.81–10.53; p = 0.001), and HHS ≥3 (odds ratio, 3.59; 95% CI, 1.50–8.61; p = 0.004). A nomogram for SDHC risk prediction was developed based on the weight of these 3 factors.
CONCLUSIONS Age, treatment modality (clipping vs coiling), and HHS are predictive for SDHC after aSAH. Endovascular embolization of aneurysm plays an important role in reducing risk of SDHC after aSAH.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Kaohsiung Veterans General Hospital Committee of Human Research/Grant no: KSVGH22-CT8-03 gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
